Page 1,348«..1020..1,3471,3481,3491,350..1,3601,370..»

About HCG Diet – HCG Diet

Posted: November 6, 2018 at 1:44 pm

Attention: Individual results may vary from the personal experiences listed on this page. Due to their unique experiences, body types and strictness to the program there are no guarantees for others, who have used or plan to use HCG Triumph, see the same results. Information provided within our site and marketing material is based on historical research, literature and results from the many thousands of former HCG (Human Chorionic Gonaditropin) Triumph clients. The personal experiences listed on this page were submitted for entry to a contest held by HCG Triumph. A before and after photo along with our clients story was required for eligibility to receive a prize. Contact your HCG Triumph weight loss support team now for any questions or concerns. Statements regarding HCG Triumph have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat or cure any disease. FDA STATEMENT: HCG has no known effects on fat mobilization, appetite or sense of hunger, or body fat distribution. HCG has not been demonstrated to be effective adjunctive therapy in the treatment of obesity. There is no substantial evidence that it increases weight loss beyond that resulting from caloric restriction, that it causes a more attractive or "normal" distribution of fat, or that it decreases the hunger and discomfort associated with calorie restricted diets.

See the rest here:
About HCG Diet - HCG Diet

Posted in HCG Diet | Comments Off on About HCG Diet – HCG Diet

Stem Cell Therapy | Ohio Stem Cell

Posted: November 5, 2018 at 3:44 pm

Amniotic regenerative cell therapy is one of the newest and most cutting-edge therapies for chronic joint pain. Amniotic derived regenerative cell therapy offers patients 3 essential properties for healing and restoring joint health:

Since amniotic derived regenerative cell therapy is not derived from embryonic stem cells or fetal tissue, there are no ethical issues with the treatment. The amniotic regenerative cell therapy consists of an injection directly into the painful area. The therapy has the potential to actually alter the course of the condition and not simply mask the pain. This therapy has significant potential for those in pain, and could actually repair structural problems while treating pain and inflammation simultaneously. When the amniotic cell material is obtained, it comes from consenting donors who have undergone elective c-sections. The fluid is processed at an FDA regulated lab, and is checked for a full slate of diseases per FDA guidelines. The amniotic material has been used over 60,000 times in the US with no adverse events reported. It acts as an immunologically privileged material, meaning it has NOT been shown to cause any rejection reaction in the body. This means there is no graft versus host problem.

Our services are provided by Dr. John Biery D.O. F.A.O.S.M. F.A.C.S.M. F.A.C.O.F.P

Lauren Sherer P.A.

Read more here:
Stem Cell Therapy | Ohio Stem Cell

Posted in Ohio Stem Cells | Comments Off on Stem Cell Therapy | Ohio Stem Cell

Human genetic clustering – Wikipedia

Posted: November 3, 2018 at 6:45 am

Human genetic clustering is the degree to which human genetic variation can be partitioned into a small number of groups or clusters. A leading method of analysis uses mathematical cluster analysis of the degree of similarity of genetic data between individuals and groups in order to infer population structures and assign individuals to hypothesized ancestral groups. A similar analysis can be done using principal components analysis,[1] and several recent studies deploy both methods.[2][3]

Analysis of genetic clustering examines the degree to which regional groups differ genetically, the categorization of individuals into clusters, and what can be learned about human ancestry from this data. There is broad scientific agreement that a relatively small fraction of human genetic variation occurs between populations, continents, or clusters. Researchers of genetic clustering differ, however, on whether genetic variation is principally clinal or whether clusters inferred mathematically are important and scientifically useful.

One of the underlying questions regarding the distribution of human genetic diversity is related to the degree to which genes are shared between the observed clusters. It has been observed repeatedly that the majority of variation observed in the global human population is found within populations. This variation is usually calculated using Sewall Wright's fixation index (FST), which is an estimate of between to within group variation. The degree of human genetic variation is a little different depending upon the gene type studied, but in general it is common to claim that ~85% of genetic variation is found within groups, ~610% between groups within the same continent and ~610% is found between continental groups. Ryan Brown and George Armelagos described this as "a host of studies [that have] concluded that racial classification schemes can account for only a negligible proportion of human genetic diversity," including the studies listed in the table below.

(rather than among populations)

diversity[4]

Cavalli-Sforza

microsatellite loci

These average numbers, however, do not mean that every population harbors an equal amount of diversity. In fact, some human populations contain far more genetic diversity than others, which is consistent with the likely African origin of modern humans.[7][8] Therefore, populations outside of Africa may have undergone serial founder effects that limited their genetic diversity.[7][8]

The FST statistic has come under criticism by A. W. F. Edwards[9] and Jeffrey Long and Rick Kittles.[10] British statistician and evolutionary biologist A. W. F. Edwards faulted Lewontin's methodology for basing his conclusions on simple comparison of genes and rather on a more complex structure of gene frequencies. Long and Kittles' objection is also methodological: according to them the FST is based on a faulty underlying assumptions that all populations contain equally genetic diverse members and that continental groups diverged at the same time. Sarich and Miele have also argued that estimates of genetic difference between individuals of different populations understate differences between groups because they fail to take into account human diploidy.[11]

Keith Hunley, Graciela Cabana, and Jeffrey Long created a revised statistical model to account for unequally divergent population lineages and local populations with differing degrees of diversity. Their 2015 paper applies this model to the Human Genome Diversity Project sample of 1,037 individuals in 52 populations.[8] They found that least diverse population examined, the Surui, "harbors nearly 60% of the total species diversity." Long and Kittles had noted earlier that the Sokoto people of Africa contains virtually all of human genetic diversity.[12] Their analysis also found that non-African populations are a taxonomic subgroup of African populations, that "some African populations are equally related to other African populations and to non-African populations," and that "outside of Africa, regional groupings of populations are nested inside one another, and many of them are not monophyletic."[8]

Multiple studies since 1972 have backed up the claim that, "The average proportion of genetic differences between individuals from different human populations only slightly exceeds that between unrelated individuals from a single population."[13][4][14][5][15][16][17]

Edwards (2003) claims, "It is not true, as Nature claimed, that 'two random individuals from any one group are almost as different as any two random individuals from the entire world'" and Risch et al. (2002) state "Two Caucasians are more similar to each other genetically than a Caucasian and an Asian." However Bamshad et al. (2004) used the data from Rosenberg et al. (2002) to investigate the extent of genetic differences between individuals within continental groups relative to genetic differences between individuals between continental groups. They found that though these individuals could be classified very accurately to continental clusters, there was a significant degree of genetic overlap on the individual level, to the extent that, using 377 loci, individual Europeans were about 38% of the time more genetically similar to East Asians than to other Europeans.

Witherspoon et al. (2007) have argued that even when individuals can be reliably assigned to specific population groups, it may still be possible for two randomly chosen individuals from different populations/clusters to be more similar to each other than to a randomly chosen member of their own cluster, when sampling a small number of SNPs (as in the case with scientists James Watson, Craig Venter and Seong-Jin Kim). They state that using around one-thousand SNPs, individuals from different populations/clusters are never more similar, which they state some may find surprising. Witherspoon et al. conclude that "caution should be used when using geographic or genetic ancestry to make inferences about individual phenotypes".

A 1994 study by Cavalli-Sforza and colleagues evaluated genetic distances among 42 native populations based on 120 blood polymorphisms. The populations were grouped into nine clusters: African (sub-Saharan), Caucasoid (European), Caucasoid (extra-European), northern Mongoloid (excluding Arctic populations), northeast Asian Arctic, southern Mongoloid (mainland and insular Southeast Asia), Pacific islander, New Guinean and Australian, and American (Amerindian). Although the clusters demonstrate varying degrees of homogeneity, the nine-cluster model represents a majority (80 out of 120) of single-trait trees and is useful in demonstrating the phenetic relationship among these populations.[19]

The greatest genetic distance between two continents is between Africa and Oceania, at 0.2470. This measure of genetic distance reflects the isolation of Australia and New Guinea since the end of the Last Glacial Maximum, when Oceania was isolated from mainland Asia due to rising sea levels. The next-largest genetic distance is between Africa and the Americas, at 0.2260. This is expected, since the longest geographic distance by land is between Africa and South America. The shortest genetic distance, 0.0155, is between European and extra-European Caucasoids. Africa is the most genetically divergent continent, with all other groups more related to each other than to sub-Saharan Africans. This is expected, according to the single-origin hypothesis. Europe has a general genetic variation about three times less than that of other continents; the genetic contribution of Asia and Africa to Europe is thought to be two-thirds and one-third, respectively.[19][20]

Genetic structure studies are carried out using statistical computer programs designed to find clusters of genetically similar individuals within a sample of individuals. Studies such as those by Risch and Rosenberg use a computer program called STRUCTURE to find human populations (gene clusters). It is a statistical program that works by placing individuals into one of an arbitrary number of clusters based on their overall genetic similarity, many possible pairs of clusters are tested per individual to generate multiple clusters.[21] The basis for these computations are data describing a large number of single nucleotide polymorphisms (SNPs), genetic insertions and deletions (indels), microsatellite markers (or short tandem repeats, STRs) as they appear in each sampled individual. Cluster analysis divides a dataset into any prespecified number of clusters.

These clusters are based on multiple genetic markers that are often shared between different human populations even over large geographic ranges. The notion of a genetic cluster is that people within the cluster share on average similar allele frequencies to each other than to those in other clusters. (A. W. F. Edwards, 2003 but see also infobox "Multi Locus Allele Clusters") In a test of idealised populations, the computer programme STRUCTURE was found to consistently underestimate the numbers of populations in the data set when high migration rates between populations and slow mutation rates (such as single-nucleotide polymorphisms) were considered.[22] In 2004, Lynn Jorde and Steven Wooding argued that "Analysis of many loci now yields reasonably accurate estimates of genetic similarity among individuals, rather than populations. Clustering of individuals is correlated with geographic origin or ancestry."[23]

A number of genetic cluster studies have been conducted since 2002, including the following:

In a 2005 paper, Rosenberg and his team acknowledged that findings of a study on human population structure are highly influenced by the way the study is designed.[28][29] They reported that the number of loci, the sample size, the geographic dispersion of the samples and assumptions about allele-frequency correlation all have an effect on the outcome of the study.

In a review of studies of human genome diversity, Guido Barbujani and colleagues note that various cluster studies have identified different numbers of clusters with different boundaries. They write that discordant patterns of genetic variation and high within-population genetic diversity "make[] it difficult, or impossible, to define, once and for good, the main genetic clusters of humankind."[7]

Genetic clustering was also criticized by Penn State anthropologists Kenneth Weiss and Brian Lambert. They asserted that understanding human population structure in terms of discrete genetic clusters misrepresents the path that produced diverse human populations that diverged from shared ancestors in Africa. Ironically, by ignoring the way population history actually works as one process from a common origin rather than as a string of creation events, structure analysis that seems to present variation in Darwinian evolutionary terms is fundamentally non-Darwinian."[30]

A major finding of Rosenberg and colleagues (2002) was that when five clusters were generated by the program (specified as K=5), "clusters corresponded largely to major geographic regions." Specifically, the five clusters corresponded to Africa, Europe plus the Middle East plus Central and South Asia, East Asia, Oceania, and the Americas. The study also confirmed prior analyses by showing that, "Within-population differences among individuals account for 93 to 95% of genetic variation; differences among major groups constitute only 3 to 5%."

Rosenberg and colleagues (2005) have argued, based on cluster analysis, that populations do not always vary continuously and a population's genetic structure is consistent if enough genetic markers (and subjects) are included. "Examination of the relationship between genetic and geographic distance supports a view in which the clusters arise not as an artifact of the sampling scheme, but from small discontinuous jumps in genetic distance for most population pairs on opposite sides of geographic barriers, in comparison with genetic distance for pairs on the same side. Thus, analysis of the 993-locus dataset corroborates our earlier results: if enough markers are used with a sufficiently large worldwide sample, individuals can be partitioned into genetic clusters that match major geographic subdivisions of the globe, with some individuals from intermediate geographic locations having mixed membership in the clusters that correspond to neighboring regions." They also wrote, regarding a model with five clusters corresponding to Africa, Eurasia (Europe, Middle East, and Central/South Asia), East Asia, Oceania, and the Americas: "For population pairs from the same cluster, as geographic distance increases, genetic distance increases in a linear manner, consistent with a clinal population structure. However, for pairs from different clusters, genetic distance is generally larger than that between intracluster pairs that have the same geographic distance. For example, genetic distances for population pairs with one population in Eurasia and the other in East Asia are greater than those for pairs at equivalent geographic distance within Eurasia or within East Asia. Loosely speaking, it is these small discontinuous jumps in genetic distanceacross oceans, the Himalayas, and the Saharathat provide the basis for the ability of STRUCTURE to identify clusters that correspond to geographic regions".[31]

Rosenberg stated that their findings "should not be taken as evidence of our support of any particular concept of biological race (...). Genetic differences among human populations derive mainly from gradations in allele frequencies rather than from distinctive 'diagnostic' genotypes."[24] The study's overall results confirmed that genetic difference within populations is between 93 and 95%. Only 5% of genetic variation is found between groups.[28]

The Rosenberg study has been criticised on several grounds.

The existence of allelic clines and the observation that the bulk of human variation is continuously distributed, has led some scientists to conclude that any categorization schema attempting to partition that variation meaningfully will necessarily create artificial truncations. (Kittles & Weiss 2003). It is for this reason, Reanne Frank argues, that attempts to allocate individuals into ancestry groupings based on genetic information have yielded varying results that are highly dependent on methodological design.[32] Serre and Pbo (2004) make a similar claim:

The absence of strong continental clustering in the human gene pool is of practical importance. It has recently been claimed that "the greatest genetic structure that exists in the human population occurs at the racial level" (Risch et al. 2002). Our results show that this is not the case, and we see no reason to assume that "races" represent any units of relevance for understanding human genetic history.

In a response to Serre and Pbo (2004), Rosenberg et al. (2005) maintain that their clustering analysis is robust. Additionally, they agree with Serre and Pbo that membership of multiple clusters can be interpreted as evidence for clinality (isolation by distance), though they also comment that this may also be due to admixture between neighbouring groups (small island model). Thirdly they comment that evidence of clusterdness is not evidence for any concepts of "biological race".[26]

Clustering does not particularly correspond to continental divisions. Depending on the parameters given to their analytical program, Rosenberg and Pritchard were able to construct between divisions of between 4 and 20 clusters of the genomes studied, although they excluded analysis with more than 6 clusters from their published article. Probability values for various cluster configurations varied widely, with the single most likely configuration coming with 16 clusters although other 16-cluster configurations had low probabilities. Overall, "there is no clear evidence that K=6 was the best estimate" according to geneticist Deborah Bolnick (2008:76-77).[33] The number of genetic clusters used in the study was arbitrarily chosen. Although the original research used different number of clusters, the published study emphasized six genetic clusters. The number of genetic clusters is determined by the user of the computer software conducting the study. Rosenberg later revealed that his team used pre-conceived numbers of genetic clusters from six to twenty "but did not publish those results because Structure [the computer program used] identified multiple ways to divide the sampled individuals". Dorothy Roberts, a law professor, asserts that "there is nothing in the team's findings that suggests that six clusters represent human population structure better than ten, or fifteen, or twenty."[34] When instructed to find two clusters, the program identified two populations anchored around by Africa and by the Americas. In the case of six clusters, the entirety of Kalesh people, an ethnic group living in Northern Pakistan, was added to the previous five.[28][35]

Commenting on Rosenberg's study, law professor Dorothy Roberts wrote that "the study actually showed that there are many ways to slice the expansive range of human genetic variation.

Sarah A. Tishkoff and colleagues analyzed a global sample consisting of 952 individuals from the HGDP-CEPH survey, 2432 Africans from 113 ethnic groups, 98 African Americans, 21 Yemenites, 432 individuals of Indian descent, and 10 Native Australians. A global STRUCTURE analysis of these individuals examined 1327 polymorphic markers, including of 848 STRs, 476 indels, and 3 SNPs. The authors reported cluster results for K=2 to K=14. Within Africa, six ancestral clusters were inferred through Bayesian analysis, which were closely linked with ethnolinguistic heritage. Bantu populations grouped with other Niger-Congo-speaking populations from West Africa. African Americans largely belonged to this Niger-Congo cluster, but also had significant European ancestry. Nilo-Saharan populations formed their own cluster. Chadic populations clustered with the Nilo-Saharan groups, suggesting that most present-day Chadic speakers originally spoke languages from the Nilo-Saharan family and later adopted Afro-Asiatic languages. Nilotic populations from the African Great Lakes largely belonged to this Nilo-Saharan cluster too, but also had some Afro-Asiatic influence due to assimilation of Cushitic groups over the last 3,000 years. Khoisan populations formed their own cluster, which grouped closest with the Pygmy cluster. The Cape Coloured showed assignments from the Khoisan, European and other clusters due to the population's mixed heritage. The Hadza and Sandawe populations formed their own cluster. An Afro-Asiatic cluster was also discerned, with the Afro-Asiatic speakers from North Africa and the Horn of Africa forming a contiguous group. Afro-Asiatic speakers in the Great Lakes region largely belonged to this Afro-Asiatic cluster as well, but also had some Bantu and Nilotic influence due to assimilation of adjacent groups over the last 3,000 years. The remaining inferred ancestral clusters were associated with European, Middle Eastern, Oceanian, Indian, Native American and East Asian populations.[36]

Jinchuan Xing and colleagues used an alternate dataset of human genotypes including HapMap samples and their own samples (296 new individuals from 13 populations), for a total of 40 populations distributed roughly evenly across the Earth's land surface. They found that the alternate sampling reduced the FST estimate of inter-population differences from 0.18 to 0.11, suggesting that the higher number may be an artifact of uneven sampling. They conducted a cluster analysis using the ADMIXTURE program and found that "genetic diversity is distributed in a more clinal pattern when more geographically intermediate populations are sampled."[3]

A study by the HUGO Pan-Asian SNP Consortium in 2009 using the similar principal components analysis found that East Asian and South-East Asian populations clustered together, and suggested a common origin for these populations. At the same time they observed a broad discontinuity between this cluster and South Asia, commenting "most of the Indian populations showed evidence of shared ancestry with European populations". It was noted that "genetic ancestry is strongly correlated with linguistic affiliations as well as geography".[37]

Studies of clustering reopened a debate on the scientific reality of race, or lack thereof. In the late 1990s Harvard evolutionary geneticist Richard Lewontin stated that "no justification can be offered for continuing the biological concept of race. (...) Genetic data shows that no matter how racial groups are defined, two people from the same racial group are about as different from each other as two people from any two different racial groups.[38] This view has been affirmed by numerous authors[14][5][16] and the American Association of Physical Anthropologists since.[10] A.W.F. Edwards as well as Rick Kittles and Jeffrey Long have criticized Lewontin's methodology, with Long noting that there are more similarities between humans and chimpanzees than differences, and more genetic variation within chimps and humans than between them.[10] Edwards also charged that Lewontin made an "unjustified assault on human classification, which he deplored for social reasons".[39] In their 2015 article, Keith Hunley, Graciela Cabana, and Jeffrey Long recalculate the apportionment of human diversity using a more complex model than Lewontin and his successors. They conclude: "In sum, we concur with Lewontins conclusion that Western-based racial classifications have no taxonomic significance, and we hope that this research, which takes into account our current understanding of the structure of human diversity, places his seminal finding on firmer evolutionary footing."[8]

Genetic clustering studies, and particularly the five-cluster result published by Rosenberg's team in 2002, have been interpreted by journalist Nicholas Wade, evolutionary biologist Armand Marie Leroi, and others as demonstrating the biological reality of race.[40][41][42] For Leroi, "Race is merely a shorthand that enables us to speak sensibly, though with no great precision, about genetic rather than cultural or political differences." He states that, "One could sort the world's population into 10, 100, perhaps 1,000 groups", and describes Europeans, Basques, Andaman Islanders, Ibos, and Castillians each as a "race".[42] In response to Leroi's claims, the Social Science Research Council convened a panel of experts to discuss race and genomics online.[43] In their 2002 and 2005 papers, Rosenberg and colleagues disagree that their data implies the biological reality of race.[24][26]

In 2006, Lewontin wrote that any genetic study requires some priori concept of race or ethnicity in order to package human genetic diversity into a defined, limited number of biological groupings. Informed by genetics, zoologists have long discarded the concept of race for dividing groups of non-human animal populations within a species. Defined on varying criteria, in the same species a widely varying number of races could be distinguished. Lewontin notes that genetic testing revealed that "because so many of these races turned out to be based on only one or two genes, two animals born in the same litter could belong to different 'races'".[44]

Studies that seek to find genetic clusters are only as informative as the populations they sample. For example, Risch and Burchard relied on two or three local populations from five continents, which together were supposed to represent the entire human race.[28] Another genetic clustering study used three sub-Saharan population groups to represent Africa; Chinese, Japanese, and Cambodian samples for East Asia; Northern European and Northern Italian samples to represent "Caucasians". Entire regions, subcontinents, and landmasses are left out of many studies. Furthermore, social geographical categories such "East Asia" and "Caucasians" were not defined. "A handful of ethnic groups to symbolize an entire continent mimic a basic tenet of racial thinking: that because races are composed of uniform individuals, anyone can represent the whole group" notes Roberts.[28][45][46]

The model of Big Few fails when including overlooked geographical regions such as India. The 2003 study which examined fifty-eight genetic markers found that Indian populations owe their ancestral lineages to Africa, Central Asia, Europe, and southern China.[47][48] Reardon, from Princeton University, asserts that flawed sampling methods are built into many genetic research projects. The Human Genome Diversity Project (HGDP) relied on samples which were assumed to be geographically separate and isolated.[49] The relatively small sample sizes of indigenous populations for the HGDP do not represent the human species' genetic diversity, nor do they portray migrations and mixing population groups which has been happening since prehistoric times. Geographic areas such as the Balkans, the Middle East, North and East Africa, and Spain are seldom included in genetic studies.[28][50] East and North African indigenous populations, for example, are never selected to represent Africa because they do not fit the profile of "black" Africa. The sampled indigenous populations of the HGDP are assumed to be "pure"; the law professor Roberts claims that "their unusual purity is all the more reason they cannot stand in for all the other populations of the world that marked by intermixture from migration, commerce, and conquest."[28]

King and Motulsky, in a 2002 Science article, state that "While the computer-generated findings from all of these studies offer greater insight into the genetic unity and diversity of the human species, as well as its ancient migratory history, none support dividing the species into discrete, genetically determined racial categories".[51] Cavalli-Sforza asserts that classifying clusters as races would be a "futile exercise" because "every level of clustering would determine a different population and there is no biological reason to prefer a particular one". Bamshad, in 2004 paper published in Nature, asserts that a more accurate study of human genetic variation would use an objective sampling method, which would choose populations randomly and systematically across the world, including those populations which are characterized by historical intermingling, instead of cherry-picking population samples which fit a priori concepts of racial classification. Roberts states that "if research collected DNA samples continuously from region to region throughout the world, they would find it impossible to infer neat boundaries between large geographical groups."[28][52][53][54]

Anthropologists such as C. Loring Brace,[55] philosophers Jonathan Kaplan and Rasmus Winther,[56][56][57][58] and geneticist Joseph Graves,[59] have argued that while it is certainly possible to find biological and genetic variation that corresponds roughly to the groupings normally defined as "continental races", this is true for almost all geographically distinct populations. The cluster structure of the genetic data is therefore dependent on the initial hypotheses of the researcher and the populations sampled. When one samples continental groups the clusters become continental; if one had chosen other sampling patterns the clustering would be different. Weiss and Fullerton have noted that if one sampled only Icelanders, Mayans and Maoris, three distinct clusters would form and all other populations could be described as being clinally composed of admixtures of Maori, Icelandic and Mayan genetic materials.[60] Kaplan and Winther therefore argue that seen in this way both Lewontin and Edwards are right in their arguments. They conclude that while racial groups are characterized by different allele frequencies, this does not mean that racial classification is a natural taxonomy of the human species, because multiple other genetic patterns can be found in human populations that cross-cut racial distinctions. Moreover, the genomic data under-determines whether one wishes to see subdivisions (i.e., splitters) or a continuum (i.e., lumpers). Under Kaplan and Winther's view, racial groupings are objective social constructions (see Mills 1998 [61]) that have conventional biological reality only insofar as the categories are chosen and constructed for pragmatic scientific reasons.

Commercial ancestry testing companies, who use genetic clustering data, have been also heavily criticized. Limitations of genetic clustering are intensified when inferred population structure is applied to individual ancestry. The type of statistical analysis conducted by scientists translates poorly into individual ancestry because they are looking at difference in frequencies, not absolute differences between groups. Commercial genetic genealogy companies are guilty of what Pillar Ossorio calls the "tendency to transform statistical claims into categorical ones".[62] Not just individuals of the same local ethnic group, but two siblings may end up beings as members of different continental groups or "races" depending on the alleles they inherit.[28]

Many commercial companies use data from the International HapMap Project (HapMap)'s initial phrase, where population samples were collected from four ethnic groups in the world: Han Chinese, Japanese, Yoruba Nigerian, and Utah residents of Northern European ancestry. If a person has ancestry from a region where the computer program does not have samples, it will compensate with the closest sample that may have nothing to do with the customer's actual ancestry: "Consider a genetic ancestry testing performed on an individual we will call Joe, whose eight great-grandparents were from southern Europe. The HapMap populations are used as references for testing Joe's genetic ancestry. The HapMap's European samples consist of "northern" Europeans. In regions of Joe's genome that vary between northern and southern Europe (such regions might include the lactase gene), the genetic ancestry test is using the HapMap reference population is likely to incorrectly assign the ancestry of that portion of the genome to a non-European population because that genomic region will appear to be more similar to the HapMap's Yoruba or Han Chinese samples than to Northern European samples.[63] Likewise, a person having Western European and Western African ancestries may have ancestors from Western Europe and West Africa, or instead be assigned to East Africa where various ancestries can be found.[64] "Telling customers that they are a composite of several anthropological groupings reinforces three central myths about race: that there are pure races, that each race contains people who are fundamentally the same and fundamentally different from people in other races, and that races can be biologically demarcated." Many companies base their findings on inadequate and unscientific sampling methods. Researchers have never sampled the world's populations in a systematic and random fashion.[28]

Roberts argues against the use of broad geographical or continental groupings: "molecular geneticists routinely refer to African ancestry as if everyone on the continent is more similar to each other than they are to people of other continents, who may be closer both geographically and genetically.[28] Ethiopians have closer genetic affinity with Armenians than with Bantu populations.[65] Similarly, Somalis are genetically more similar to Gulf Arab populations than to other populations in Africa.[66] Braun and Hammonds (2008) asserts that the misperception of continents as natural population groupings is rooted in the assumption that populations are natural, isolated, and static. Populations came to be seen as "bounded units amenable to scientific sampling, analysis, and classification".[67] Human beings are not naturally organized into definable, genetically cohesive populations.

Software which support genetic clustering calculation.

Go here to read the rest:
Human genetic clustering - Wikipedia

Posted in Human Genetics | Comments Off on Human genetic clustering – Wikipedia

Ohio Stem Cell Treatment Center of Cleveland (Beachwood …

Posted: November 3, 2018 at 6:44 am

Order By RankOrder By PopularityOrder By Posted DateOrder By Title

10 Items Per Page20 Items Per Page40 Items Per Page60 Items Per Page80 Items Per Page100 Items Per Page

Our adipose derived stem cell harvesting and isolation technique yields extremely high numbers of stem cells. In reviewing outcomes data, treatment cell numbers appear to correlate with treatment success. Our cells are actually in a type of soup called Stromal Vascular Fraction SVF which is stem cells bathed in a rich mixture of natural growth factors (Not the same as human growth factor hormone which is only one type of growth factor). Some types of orthopedic and urologic diseases appear to respond better to stem cells that are super enriched with growth factors created by administering Platelet Rich Plasma to the patient. Autologous Platelet Rich Plasma is derived from a patient's own blood drawn at the time of deployment. At CSN we do not add any foreign substances or medications to the stem cells.

Yes. Patients with uncontrolled cancer are excluded. If you have an active infection anywhere in your body you must be treated first. Severely ill patients may require special consideration. Also, anyone with a bleeding disorder or who takes blood thinning medications requires special evaluation before consideration for stem cells.

We know of no documented cases personally or in the literature where serious harm has resulted. All of our patients will be entered into a database to follow and report any adverse reactions. This information is vital to the development of stem cell science. There have been a few reports of serious complications from overseas and these are being thoroughly evaluated by epidemiologists to ascertain the facts. The International Stem Cell Society registry has over 1,000 cases currently registered and only 2% of the treatments were associated with any complications, none of which were considered serious adverse events.

Stem cells can be cryopreserved in the form of liposuction fat for prolonged periods of time. Currently, this service is outsourced to an outside provider known to have excellent quality control. Many patients have been inquiring about banking cells while they are still young since stem cell numbers drop naturally with each decade of life and some advocate obtaining and saving cells to be used later in life as needed.

Different conditions are treated in different ways and there are different degrees of success. If the goal is regeneration of joint cartilage, one may not see expected results until several months after treatment. Some patients may not experience significant improvement and others may see dramatic regeneration of damaged tissue or resolution of disease. Many of the disorders and problems that the physicians at CSN are treating represent pioneering work and there is a lack of data. FDA regulations prevent CSN from making any claims about expectations for success, however, if you are chosen for treatment, it will be explained that we believe stem cell therapy may be beneficial or in some cases that we are unsure and treatment would be considered investigational.

Adult mesenchymal stem cells are not known to cause cancer. Some patients have heard of stories of cancer caused by stem cells, but these are probably related to the use of embryonic cells (Not Adult Mesenchymal Cells). These embryonic tumors known as teratomas are rare but possible occurrences when embryonic cells are used.

No. Many are confused by this because they have heard of cancer patients receiving stem cell transplants. These patients had ablative bone marrow therapy and need stem cells to re-populate their blood and marrow. This is different from the stem cells we deploy to treat noncancerous human diseases at CSN.

No. Only adult mesenchymal stem cells are used. These cells are capable of forming bone, cartilage, fat, muscle, ligaments, blood vessels, and certain organs. Embryonic stem cells are associated with ethical considerations and limitations.

No. Only a person's own adult autologous cells are used. These are harvested from each individual and deployed back into their own body. There is no risk of contamination or risk of introduction of mammalian DNA into the treatments.

Depending on the type of treatment required, stem cells can be injected through veins, arteries, into spinal fluid, subcutaneously, or directly into joints or organs. All of these are considered minimally invasive methods of introducing the stem cells. Stem cells injected intravenously are known to seek out and find (see photo) areas of tissue damage and migrate to that location thus potentially providing regenerative healing. Intravenously injected stem cells have been shown to have the capability of crossing the blood-brain barrier to enter the central nervous system and they can be identified in the patient's body many months after deployment. Note yellow arrow showing the stem cells concentrated in the patient's hand where he had a Dupytren's contracture (Dupuytren's contracture is a hand deformity that causes the tissue beneath the surface of the hand to thicken and contract).

These adult stem cells are known as progenitor cells. This means they remain dormant (do nothing) unless they witness some level of tissue injury. It's the tissue injury that turns them on. So, when a person has a degenerative type problem, the stem cells tend to go to that area of need and stimulate the healing process. We're still not sure if they simply change into the type of injured tissue needed for repair or if they send out signals that induces the repair by some other mechanism. Suffice it to say that there are multiple animal models and a plethora of human evidence that indicates these are significant reparative cells.

Stem cells are harvested under sterile conditions using a special closed system technology so that the cells never come into contact with the environment throughout the entire process from removal to deployment. Sterile technique and antibiotics are also used to prevent infection.

Ohio Stem Cell Treatment Center patients have their fat (usually abdominal) harvested in our special sterile treatment facility under a local anesthetic. The fat removal procedure lasts approximately twenty minutes. Specially designed equipment is used to harvest the fat cells and less than 100cc of fat is required. Post operative discomfort is minimal and there is minimal restriction on activity.

Stem cell therapy relies on the body's own regenerative healing to occur. The regenerative process may take time, particularly with orthopedic patients, who may not see results for several months. In some diseases, more immediate responses are possible.

Most patients, especially those with orthopedic conditions, require only one deployment. Certain types of degenerative conditions, particularly auto-immune disease, may respond best to a series of stem cell deployments. The number and necessity of any additional treatments would be decided on a case by case basis. Financial consideration is given in these instances.

No. Only certain medical problems are currently being treated at CSN. Check our list or fill out a candidate application form on the website. All patients need to be medically stable enough to have the treatment in our facility. There may be some exceptional conditions that may eventually be treated in hospitalized patients, but that remains for the future. Some patients may be declined due to the severity of their problem. Other patients may not have conditions appropriate to treat or may not be covered by our specialists or our protocols. A waiting list or outside referral (if we know of someone else treating such a problem) might be applicable in such cases.

NO. However, the Cell Surgical Network's procedures fall under the category of physician's practice of medicine, wherein the physician and patient are free to consider their chosen course of treatment. The FDA does have guidelines about treatment and manipulation of a patient's own tissues. At CSN we meet these guidelines by providing same day treatment with the patient's own cells that undergo very minimal manipulation and are inserted during the same procedure.

Stem cells are harvested and deployed during the same procedure. Our patients undergo a minimally-invasive liposuction type of harvesting procedure by a Board Certified cosmetic surgeon in our specialized treatment facility in a Treatment Center closest to you. The harvesting procedure generally lasts a few minutes and can be done under local anesthesia. Cells are then processed and are ready for deployment within 90 minutes or less.

CSN is doing pioneer research and treatment of many diseases. All investigational data is being collected so that results will be published in peer review literature and ultimately used to promote the advancement of cellular based regenerative medicine. FDA regulations mandate that no advertising medical claims be made and that even website testimonials are prohibited.

Stem cell therapy is thought to be safe and not affect dormant cancers. If someone has had cancer that was treated and responded sucessfully, there is know reason to withhold stem cell deployment. In most cases, stem cells should not be used in patients with known active cancer.

Results 1 - 20 of 37

More here:
Ohio Stem Cell Treatment Center of Cleveland (Beachwood ...

Posted in Ohio Stem Cells | Comments Off on Ohio Stem Cell Treatment Center of Cleveland (Beachwood …

Adoptive T Cell Therapy 2: Development

Posted: November 2, 2018 at 7:41 am

Cambridge Healthtech Institutes 5th AnnualAugust 30-31, 2018

In 2017, two CAR T cell therapies were approved by the Food and Drug Administration (FDA). With multiple engineered receptors making preclinical impact, many biotech and pharma companies are already entering other clinical trials in a race to get to market. Has this promising field finally reached a tipping point? Technical considerations and translational challenges relating to cell therapy development, manufacturing practicability, clinical trial approaches, cell quality and persistence, and patient management remain. Cambridge Healthtech Institutes 5th Annual Adoptive T Cell Therapy 2: Development conference focuses on the steps needed to deliver CAR, TCR, NK, and TIL therapies to the clinic. Overall, this event addresses clinical progress, case studies, and the critical components for making adoptive T cell therapy work.

Final Agenda

Day 1 | Day 2 | Download BrochureSpeaker Biographies | Participating Companies | Emerging Company Showcase Presenters

THURSDAY, August 30

7:45 am Registration & Morning Coffee (Harbor Level)

8:25 Chairpersons Opening Remarks

Amy Hines, BSN, RN, Director, Collection Network Management, Be The Match BioTherapies

8:30 FEATURED PRESENTATION: A Translational Perspective of Development of Yescarta (Axicabtagene Ciloleucel), a First-in-Class CAR T Cell Product for Diffuse Large B Cell Lymphoma

Adrian Bot, MD, PhD, Vice President, Translational Sciences, Kite, a Gilead Company

Yescarta (Axicabtagene Ciloleucel) is an anti-CD19 CAR T cell therapy that received approval for treatment of relapsing or refractory DLBCL. This presentation describes key elements of the translational program, correlates of toxicities and durable objective response, product characteristics, patient conditioning, and importance of tumor microenvironment. It also showcases major lessons learned and challenges in developing cell-based immunotherapies.

9:00 NEW: Selected Poster Presentation: TAC-T, A Novel T Cell Therapy, Co-Opts the Endogenous T Cell Receptor for Effective, Safe, and Persistent Tumor Rejection

Christopher W. Helsen, PhD, Director, R&D and Head, Platform Development, Triumvira Immunologics, Inc.

9:30 Predictors of Response to CD19-Specific CAR T Therapy in B-CLL

Jun Xu, PhD, Associate Director, Product Development Laboratory, Center for Advanced Cellular Therapeutics, Perelman Center for Advanced Medicine, University of Pennsylvania

To date, it has not been possible to identify patient- or disease-specific factors that predict why some B-CLL patients and not others have such dramatic responses to CAR T cell treatment. We explored the mechanisms associated with clinical response and lack of response to CAR T therapy, providing evidence for intrinsic T cell fitness in mediating durable anti-tumor responses and long-term complete remissions.

10:00 Coffee Break in the Exhibit Hall (Last Chance for Poster Viewing) (Commonwealth Hall)

10:45 Facing the Challenges of Apheresis Network Management

Amy Hines, BSN, RN, Director, Collection Network Management, Be The Match BioTherapies

For companies working in cell therapies, managing and maintaining your apheresis (cell collection) network is a critical challenge. How do you know which center is best equipped to handle your needs? How do you evaluate their compliance with FDA and international regulations? Hines discusses the key questions to ask and gives you the tools youll need to evaluate centers, secure your supply chain and advance your cell therapy program.

11:15 Solving the Challenges of Large-Scale GMP T Cell Manufacturing

Steven L. Highfill, PhD, Assistant Director, Product Development and Management, Center for Cellular Engineering, Clinical Center, National Institutes of Health

This presentation covers current, ongoing GMP manufacturing efforts at the NIH. Highlights focus on CAR T cell manufacturing and some of the challenges that we had to overcome specifically when using autologous patient-derived starting material. In addition, I discuss some newer closed-system manufacturing platforms that will make it easier for academic institutes to provide cell therapy options to their patients.

11:45 Sponsored Presentation (Opportunity Available)

12:15 pm Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

12:45 Session Break

1:40 Chairpersons Remarks

Adrian Bot, MD, PhD, Vice President, Translational Sciences, Kite, a Gilead Company

1:45 FEATURED PRESENTATION: Stress-Resistant T Cell Therapy for Solid Tumors

Prasad S. Adusumilli, MD, FACS, FCCP, Associate Attending and Deputy Chief, Thoracic Surgery; Head, Solid Tumors Cell Therapy, Cellular Therapeutics Center; Director, Mesothelioma Program, Memorial Sloan Kettering Cancer Center

CAR T cell therapy efficacy in solid tumors is limited by PD-1/PD-L1 pathway. We have shown that exhausted CAR T cells can be rescued by anti-PD1 agents or by a decoy receptor, PD-1 dominant negative receptor cotransduced with CAR T cells to promote functional persistence. The presentation focuses on cell-intrinsic and extrinsic methods in overcoming checkpoint blockade in cellular immunotherapy.

2:15 TRAP CAR T & Related Cell Therapies: Can Local Delivery Solve Efficacy and Safety Challenges in Solid Tumor Immuno-Oncology?

Janet R. Rea, MSPH, RAC, Senior Vice President, Regulatory, Quality & Clinical Affairs, Atossa Genetics

This presentation reviews cell therapy evolution and challenges. It includes considerations of local delivery options using breast cancer as a model.

2:45 Selected Poster Presentation: Phase I Study of an Adoptive Cellular Immunotherapy by Silencing cbl-b in Autologous Peripheral Blood Mononuclear Cells

Kathrin Thell, PhD, MSc, In Vivo Scientist, Apeiron Biologics AG

3:15 Refreshment Break (Commonwealth Hall)

3:45 Eutilexs 4-1BB CTL Adoptive T Cell Therapy: Clinically Safe and First Efficacy in Solid Tumors

Agustin de la Calle, PhD, CBO, Eutilex Co., Ltd.

Eutilexs 4-1BB CTL therapy is the autologous T cell therapy proven safe in man without treatment-related toxicity and no CRS. Efficacy in hematological cancers and solid tumors: brain, breast, lung, tracheal, pancreatic cancers, CRC and melanoma. Complete remissions were observed in Hodgkins and NK/T cell lymphomas. Phase I safety accepted single dose in terminal patients but relapsed patients became responsive again to further treatments. Leader in COGS: simple outpatient procedure.

4:15 Engineering NK Cells for Enhanced Potency and Persistence

James B. Trager, PhD, Senior Vice President, R&D, Nkarta, Inc.

NK cells form a first line of defense against cancer, and they can be formidable mediators of cytotoxicity and adaptive immunity. Efforts to maximize their potential as cancer therapeutics are hampered by difficulty in expanding NK cells, relatively short in vivo persistence, and the ability of tumor cells to evade NK recognition. We discuss recent progress in overcoming these barriers to successful therapeutic application of NK cells.

4:45 FEATURED PRESENTATION: Tricked-Out CARs: Next-Generation Approaches to Enhance and Optimize CAR T Cell Function

Benjamin Boyerinas, PhD, Senior Scientist, Immunotherapy, bluebird bio

Genetically engineered CAR T cells can be further engineered to survive and overcome immune evasion mechanisms employed by tumors. We have been developing a novel TGF- signal conversion platform that provides a T cell supportive signal upon exposure to TGF- within the hostile tumor microenvironment. This approach, combined with other methodologies such as gene editing and drug-regulated activation, have the potential to enhance specific activity within solid tumors.

5:15 End of Day

Day 1 | Day 2 | Download Brochure

FRIDAY, August 31

7:45 am Registration (Plaza Level)

8:00 Breakout Discussion Groups with Continental Breakfast (Beacon Hill)

This session features discussion groups that are led by a moderator who ensures focused conversations around the key issues listed. Attendees choose to join a specific group, and the small, informal setting facilitates sharing of ideas and active networking. Details on the topics and moderators are available on the conference website.

9:00 Chairpersons Remarks

Paul Rennert, PhD, President & CSO, Aleta Biotherapeutics, Inc.

9:05 GOLD: Activation-Induced Payload Delivery for T Cell Therapies

Gus Zeiner, PhD, CSO, Chimera Bioengineering

GOLD is an endogenous post-transcriptional gene regulatory node that couples T cell metabolic states to transgenic payload outputs. Conditional payload expression is induced by signaling through either the native T cell receptor or a CAR. GOLD is payload-agnostic, and enforces low basal payload expression in resting T cells with a wide dynamic range in activated T cells. GOLD-mediated regulation is non-immunogenic, making GOLD-enabled T cell therapeutics compatible with long-term persistence.

9:35 Developing Tumor Infiltrating Lymphocytes for the Treatment of Cancer

Maria Fardis, PhD, President & CEO, Iovance Biotherapeutics

Recent FDA approvals of Kymriah and Yescarta show that cell therapies are viable options for treatment of hematological malignancies. Incidence of solid tumors are, however, approximately 10 times higher than hematological malignancies. Available therapies for solid tumors include chemotherapy, radiotherapy, and immunotherapy. Immunotherapies, such as Anti-PD-1 antibodies, have shown promise, but in many cases, although the overall response rate is not high, discontinuation due to adverse events remains an issue. Iovance is developing -infiltrating lymphocytes (TIL), a one-time cell therapy treatment that leverages and enhances the bodys natural defenses against certain aggressive solid tumors. TIL is currently under investigation in several multi-center Phase II clinical trials and preliminary results have demonstrated safety and efficacy in melanoma, head and neck and cervical cancer patients with multiple prior therapies which constitutes unmet medical need.

10:05 PM21-NK Cells for Cancer Therapy

Robert Igarashi, PhD, President, CytoSen Therapeutics

CytoSen is advancing NK cell therapy for treatment of cancer. CytoSens methods for stimulating NK cells with membrane bound (IL21), originally developed by Dr. Dean A. Lee, produces NK cells with high anti-tumor potency and can generate the highest doses. We plan to leverage our particle-based platform, that has logistical advantages, to pursue clinical studies in leukemia.

10:35 Coffee Break (Plaza Level)

11:00 A TCR-Based Chimeric Antigen Receptor

Even Walseng, PhD, Staff Scientist, Experimental Immunology Branch, National Cancer Institute, National Institutes of Health; Department of Immunology, Hospital Radiumhospitalet, Institute for Cancer Research, University of Oslo

Although CARs are very potent, the recognition is limited to membrane antigens which represent around 1% of the total proteins expressed, whereas TCRs have the advantage of targeting any peptide resulting from cellular protein degradation. To expand the horizon of TCR use, we have successfully fused a soluble TCR construct to a CAR-signaling tail. We demonstrate that the TCR-CAR redirection is not restricted to T cells and hence opens therapeutic avenues combing the killing efficiency of NK cells with the diversified target recognition of TCRs.

11:30 Hijacking CAR19 T Cells to Address Critical Issues in Cell Therapy: Application to Diverse Indications

Paul Rennert, PhD, President & CSO, Aleta Biotherapeutics, Inc.

The Aleta platform addresses critical issues in cell therapy including CAR persistence, antigen escape and antigen heterogeneity, and provides important solutions for treating both hematologic and solid tumors. The key element of our technology is the use of novel fusion proteins to redirect CAR T specificity. Our lead programs are directed to B cell malignancies, AML and solid tumors.

12:00 Close of Adoptive T Cell Therapy 2: Development

Day 1 | Day 2 | Download BrochureSpeaker Biographies | Participating Companies | Emerging Company Showcase Presenters

The rest is here:
Adoptive T Cell Therapy 2: Development

Posted in Cell Therapy | Comments Off on Adoptive T Cell Therapy 2: Development

Stem Cell Treatments MI | Michigan Center for Renerative …

Posted: November 2, 2018 at 7:40 am

How would you like to avoid addictive medications for your chronic pain or progressive disease with a revolutionary, safe and effective alternative? Our own stem cells could provide the answers. Found mainly in our bone marrow and fat, stem cells are powerhouses of healing potential. Imagine being able to use your own stem cells to heal injury! The process itself is relatively simple, which involves isolating the stem cells, concentrating them into a syringe and injecting them where they can do the most good.

Here at The Michigan Center for Regenerative Medicine, we utilize the bone marrow stores over fat for a couple of different reasons. First, they work better for the types of conditions we treat. Second, the FDA restricts techniques aimed at isolating fat cells. Because we pride ourselves on our strict compliance with the FDA, we focus on bone marrow aspiration procedures. Virtually painless, stem cell treatments in Michigan have been used here to successfully treat conditions such as spinal disc herniations, osteoarthritis, tendonitis, bursitis, rotator cuff damage, whiplash, plantar fasciitis and much more.

Tired of pain? Looking to avoid dependence on medication or reduce your chances of surgery? We can help. To find out more, call The Michigan Center for Regenerative Medicine today for your free consultation at 248-216-1008.

Stem cell treatments in Michigan carry with them many benefits, not the least of which is to finally incorporate a treatment plan that doesnt simply mask the pain such as through pills and cortisone injections, but that truly addresses the underlying cause.

Stem cell treatments can:

Dr. Thomas S. Nabity, Jr., board-certified in physical medicine, rehabilitation and pain medicine, will conduct the procedure with his team. Harvested cells are isolated in an on-site lab using a centrifuge and flow cytometer to achieve the highest concentration of cells possible.The stem cells are then placed in a syringe and re-introduced into the targeted tissue. This all happens on the same day, performed under either x-ray or ultrasound to ensure precise location for stem cell delivery.The entire procedure takes two hours from start to finish, usually only requiring local anesthetic. However, IV sedation is available if you want it.

Scientifically proven regenerative medicine could be your solution. Every year, more and more patients opt to fix their chronic orthopedic conditions with stem cell treatments over invasive surgery. Are stem cell treatments in Michigan right for you?

We would be happy to provide you with a free consultation to answer your questions on stem cell treatments in Michigan. Please call us now at 248-216-1008.

Continue reading here:
Stem Cell Treatments MI | Michigan Center for Renerative ...

Posted in Michigan Stem Cells | Comments Off on Stem Cell Treatments MI | Michigan Center for Renerative …

Michigan Stem Cell Therapy – Foot HealthCare Associates

Posted: November 2, 2018 at 7:40 am

*Absolutely Ethical NO fetal tissue Amniotic Material only from live birth*

Stem cell grafts can be used for effective long-term treatment of:

Regenerative medicine offers solutions and hope for painful medical conditions that are resistant to traditional treatments and greatly enhance the resolution and healing for painful injuries. Therefore, there is the potential to fully heal the body by stimulating the tissues and joints to heal themselves. Regenerative medicine holds the hope of repairing damaged tissue by stimulating the body to heal from within.

Derived from the placental tissue of healthy donors after live elective Cesarean Delivery, Amniotic Stem Cells are formed from the same blastocyst that form the human fetus and Maternal placenta. Furthermore, Amniotic Stem Cellshave a remarkable ability to form into many different types of cells. They act as an internal repair center, dividing endlessly to replenish other cells. After dividing, the stem cell will do one of two things: Become another stem cell or become another type of needed specialized cell (muscle, skin, blood, brain, etc). Stem cells are the building blocks that allow us to go from a single cell organism into a complex multicellular unit.

Stem cell treatment takes advantage of the bodys ability to repair itself. The amniotic stem cells can jump-start the healing process by creating the cells the damaged tissues need.

Surgeries canbe painful and require an extended rehabilitation time. Conversely, regenerative medicine procedures such as stem cell therapy allow the body to heal itself by providing building blocks to stimulate the bodys natural healing processes.

Request a Call from Us! Register for an Appointment Online

Articles and Reference:

Basic Information

Amniotic Fluid as a rich source of mesenchymal Stromal cells for Transplantation Therapy

Amniotic Fluid Pathways& Functions

Gensano Education Link

http://www.MichiganPodiatry.com

Read more from the original source:
Michigan Stem Cell Therapy - Foot HealthCare Associates

Posted in Michigan Stem Cells | Comments Off on Michigan Stem Cell Therapy – Foot HealthCare Associates

University of Michigan Stem Cell Research | Treatment and …

Posted: November 2, 2018 at 7:40 am

Even as research continues on stem cells in U-Ms laboratories, some patients and research volunteers at the U-M Health System already receive stem cell-related therapies.

Every year, more than 200 children and adults receive transplants of stem cells at U-Ms nationally known Blood and Marrow Transplant program. Most of them have leukemia, lymphoma or other cancers.

Since December 2011, this care has had a new home: a state-of-the-art inpatient and outpatient floor within the building that also houses the new C.S. Mott Childrens Hospital and Von Voigtlander Womens Hospital.

These transplants of stem cells taken from the bone marrow or blood of the patient or a donor can save the life of a child or adult.

To learn more about U-Ms program, visit this page.

To find out how you can donate your own marrow or blood stem cells to help a patient at U-M or one of the nations other stem cell treatment sites, visit the National Marrow Donor Programs Be the Match site.

When an idea is ready to make the jump from the research laboratory to the clinic or hospital, its time to do a clinical trial. These tightly controlled tests allow patients to be our partners in developing new treatments and tests.

Many clinical trials at U-M have studied new options for blood and marrow stem cell transplant patients. Some of these studies have led to important new discoveries about how best to treat patients with leukemia, lymphoma and multiple myeloma worldwide. You can learn more about this research here.

Today, our researchers are starting to explore ways to use another kind of stem cell knowledge in fighting other diseases.

Our years of laboratory research on cancer stem cellsthe small number of cells that drive tumor growth and spread, and that are resistant to current treatmentsare now being translated into clinical trials to see how these cells can be stopped. The first trials are now under way.

Tomorrow, even more trials for other diseases could be available, as our laboratory research into other types of stem cells progresses.

To see a list of U-M stem cell trials that are currently seeking participants, visit http://www.umclinicalstudies.org and enter stem cells into the search box at the top of the page.

To learn more about how we protect the health and safety of people who take part in all types of clinical trials at U-M, visit this page.

Read more:
University of Michigan Stem Cell Research | Treatment and ...

Posted in Michigan Stem Cells | Comments Off on University of Michigan Stem Cell Research | Treatment and …

Cancer Stem Cell Research | University of Michigan Rogel …

Posted: November 2, 2018 at 7:40 am

What are adult stem cells?

Every organ and tissue in the body contains a small number of what scientists call adult stem cells or progenitor cells. These cells have three characteristics in common:

1). Adult stem cells can renew themselves through cell division for long periods of time.

2). Adult stem cells retain the ability to give rise to several (but not all) types of cells in the body.

3). Different types of adult stem cells give rise to different specialized cells. Pancreatic stem cells, for example, are the ancestors of insulin-producing islet cells in the pancreas. Hematopoietic stem cells develop into all the different types of cells in the human blood and immune systems.

Cancer stem cells are a type of adult or progenitor cell found in most types of cancer. These cells generally represent just 1% to 3% of all cells in a tumor, but they are the only cells with the ability to regenerate malignant cells and fuel the growth of the cancer.

No. Embryonic stem cells are primitive cells that form inside an early embryo. These cells also can be generated in a laboratory dish during a process called in-vitro fertilization. Four to five days after a human egg is fertilized by sperm, the dividing mass of cells is called a blastocyst. Scientists can remove the inner cell mass from the blastocyst and grow stem cells in a culture dish in the laboratory. Under the right conditions, these stem cells will retain the ability to divide and make copies of themselves indefinitely. Unlike adult stem cells, embryonic stem cells have the ability to give rise to any of the more than 200 different types of cells in the human body.

Cancer research focuses on stem cells present in malignant tumors. Researchers believe current cancer treatments sometimes fail because they don't destroy the cancer stem cells. Think of cancer as a weed: the stem cells are the root while the remaining majority of the cells are the part of the weed above ground. If you remove only the leaves but not the root, the weed will grow back. The same is true for cancer: if you do not kill the cancer stem cells, the cancer is likely to return.

In some cancer types, we are doing a good job. Most cancers when caught early can be successfully treated. But doctors still struggle to treat advanced cancers and some cancer types, such as pancreatic cancer, still have incredibly dismal survival rates. Other cancers, such as head and neck cancers, are often resistant to current therapies, making less-invasive treatments more difficult. In addition, current chemotherapies cause severe side effects because they target all rapidly dividing cells. Treatments that target only cancer stem cells would cause fewer side effects for patients.

Cancer stem cells were first identified in leukemia. U-M researchers discovered the first cancer stem cells in solid tumors, finding them in breast cancer. Since then, cancer stem cells have been identified in brain, colon, head and neck, pancreas and central nervous system tumors. Work is ongoing to identify stem cells in other tumor types.

Researchers take samples of tumors removed from patients during surgery, always with the patient's informed consent. The cells within the tumor are then sorted based on their expression of certain cell markers on their surface. Sorted cells can be injected into mice, which are then watched for new tumor growth. When only specific sorted cells form new tumors, researchers then test those cells for properties of stem cells.

The next step is to understand how cancer stem cells work and identify drugs that will kill the stem cells without harming normal cells.

The work on cancer stem cells is still in early stages, primarily taking place in the laboratory and early clinical trials. U-M is conducting clinical trials of experimental therapies targeted at cancer stem cells in multiple myeloma, pancreatic cancer and breast cancer. Initial results are positive, but additional trials in a larger number of patients will be necessary. If these new drugs are proven to be safe and effective, they could become the first approved cancer treatments to be developed as a result of cancer stem cell research.

Back to top

Updated 03.2016

Original post:
Cancer Stem Cell Research | University of Michigan Rogel ...

Posted in Michigan Stem Cells | Comments Off on Cancer Stem Cell Research | University of Michigan Rogel …

Regenerative Medicine Institute of Nevada RMinLasVegas …

Posted: November 1, 2018 at 11:50 am

Our Technology

Early stem cell research has generally been connected with the controversial utilization of embryonic stem cells. The new focus is on non-embryonic adult mesenchymal stem cells which are discovered in an individual's own blood, bone marrow, and fat.

Learn More

Treatment Process

You have made an important decision to have an stem cell deployment. Its exciting that these devices are presently accessible for therapeutic utilization. Stem cell therapy with your own stem cells might possibly be the next critical development in medicine

Learn More

Hitting retirement age or being blindsided by a sports injury doesnt mean putting your life on hold. At the Regenerative Medicine Institute of Nevada, we understand how better mobility improves quality of life. That's why we offer treatments that can help you achieve better ways to relieve chronic pain, encourage natural tissue healing and faster recovery times.

We offer stem cell therapy in Las Vegas NV to patients to treat a range of conditions. These treatments include the following:

At the Regenerative Medicine Institute of Nevada, only trained and experienced staff perform these procedures. If you need more help in deciding whether stem cell treatment is right for you, talk to us.

Go here to read the rest:
Regenerative Medicine Institute of Nevada RMinLasVegas ...

Posted in Nevada Stem Cells | Comments Off on Regenerative Medicine Institute of Nevada RMinLasVegas …

Page 1,348«..1020..1,3471,3481,3491,350..1,3601,370..»